[Clinical effect of treatment with lipo-prostaglandin E1 on the patients with chronic glomerulonephritis].
OBJECTIVE
To investigate potential mechanism underlying lipo-prostaglandin E1 (PGE1) in treatment of patients with chronic glomerulonephritis.


METHODS
The recommended dose of 20 microg lipo-PGE1 for treatment of chronic glomerulonephritis was as a daily dose by continuous intravenous infusion or intravenous injection for 4 weeks. The levels of interleukin-1 (IL- 1), tumor necrosis factor-alpha (TNF-alpha), blood urea nitrogen (BUN), serum creatinine (SCr) and clearance of creatinine (CCr) were measured before and after treatment.


RESULTS
After treatment with lipo-PGE1, levels of IL-1, TNF-alpha, BUN and SCr were lower than those before treatment (all P<0.01), but CCr values were higher than those before treatment (P<0.05).


CONCLUSIONS
Lipo-PGE1 can reduce the renal inflammatory response and improve the renal function in the patients with chronic glomerulonephritis.
Zhong
Wei-qiang
WQ
Department of Nephrology, Huizhou Center People's Hospital, Huizhou 516001, Guangdong, China.
Liu
Guan-xian
GX
Yang
Yong-ming
YM
Cai
Xun
X
Huang
Zhong-liang
ZL
D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D005260:Female; D005921:Glomerulonephritis / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D007668:Kidney / Q000473:pathology / Q000503:physiopathology; D008297:Male; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014665:Vasodilator Agents / Q000627:therapeutic use
D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D014665:Vasodilator Agents; D003404:Creatinine; D000527:Alprostadil